课题基金 / 基金详情

Accelerated Development of Pharmaceutical Processes Through Digitally Coupled Reaction Screening and Process Optimisation

Accelerated Development of Pharmaceutical Processes Through Digitally Coupled Reaction Screening and Process Optimisation
通过数字耦合反应筛选和工艺优化加速制药工艺的开发
批准号:
EP/Z531339/1
负责人:
Adam Clayton
金额:
$215.99万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2024
资助国家:
英国
项目状态:
未结题
起止时间:
2024 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
合成的开发和反应的优化仍然是制药工艺开发中的限速因素,通常依赖于昂贵、耗时和浪费的资源密集型试错方法。这突出表明需要开发能够快速应对新出现的健康挑战的新数字方法。为了实现这一目标,我们将在多个地点建立一个数字耦合反应器网络,能够进行高通量筛选和自我优化制造工艺。该提案独特地结合了不同的流动反应器技术,分析技术和自动化工作流程,以提供化学空间的增强映射和强大的高质量数据集的生成。机器人技术将用于设计灵活的实验系统,能够探索连续的(例如,时间,温度)和分类(例如,催化剂、配体)变量以及不同的反应器类型。值得注意的是,将开发并行液滴流反应器,并与智能优化算法相结合,以减少药物开发活动中所需的材料量。将建立一个多站点反应器网络,并由下一代机器学习算法驱动,该算法将利用先前实验活动的知识来提高文库合成成功率,并加速化学相关过程的开发和优化。在发现过程中进行的实验数量要比在工艺开发过程中多出几个数量级;在这个早期阶段收集的高质量自动化数据对于加速、降低成本和可持续制造至关重要。通过与制药行业的合作伙伴合作,我们将利用这种新的工作流程来简化未来药物的途径。我们的非本地化人工智能网络产生的能力和结果将在不同的化学制造行业之间转移。本研究的目标是:自主高通量微流控流动反应器的发展,用于合成药物相关的化合物库。通过整合最先进的混合变量优化算法,将提高文库合成的成功率。实时在线分析将用于量化每个反应,从而为预测性机器学习模型提供强大的标准化数据集,使其能够应用于目前尚未开发的化学领域。创建跨多个站点的数字耦合反应器,以探索广阔的工艺空间。为了实现这一目标,将利用互补的分析技术和不同的反应器技术来生成不同规模的数据集。多目标优化将考虑多个目标之间的权衡,使生产的可持续性从药物开发的一开始就考虑在内。多个实验室的不同类型数据的组合,为新的文库合成和工艺优化活动生成假设。下一代机器学习算法将被设计为使用背景相似的化学系统的先验知识,目的是加速从发现到制造的过渡。我们的数字耦合反应器网络将用于执行并行库合成和选定过程的自我优化。将使用利兹iPRD内的可用设施评价规模扩大。
英文摘要
Development of synthesis and optimisation of reactions remain rate-limiting factors in pharmaceutical process development, often relying on resource-intensive trial-and-error approaches that are costly, time-consuming, and wasteful. This highlights the need to develop new digital methods that are capable of rapidly responding to emerging health challenges. To achieve this, we will create a network of digitally coupled reactors across multiple sites capable of high-throughput screening and self-optimising manufacturing processes. This proposal uniquely combines different flow reactor technologies, analytical techniques, and automated workflows to provide enhanced mapping of chemical space and generation of robust high-quality datasets. Robotics will be used to design flexible experimental systems capable of exploring continuous (e.g., time, temperature) and categorical (e.g., catalyst, ligand) variables, as well as different reactor types. Notably, parallelised droplet flow reactors will be developed and combined with intelligent optimisation algorithms to reduce the amount of material required during pharmaceutical development campaigns. A multisite reactor network will be established and driven by next generation machine learning algorithms, which will use knowledge from prior experimental campaigns to increase library synthesis success rates and accelerate the development and optimisation of chemically related processes. Orders of magnitude more experiments are performed during discovery than during process development; the high-quality automated data collected at this early stage will be essential for accelerated, lower cost and sustainable manufacturing. In collaboration with our partners in the pharmaceutical industry, we will leverage this novel workflow to streamline the pathway to future medicines. The capabilities and results generated from our delocalised artificially intelligent network will be transferable across different chemical manufacturing sectors. The objectives of this research are:Development of autonomous high-throughput microfluidic flow reactors for the synthesis of pharmaceutically relevant compound libraries. Library synthesis success rates will be increased by integration of state-of-the-art mixed variable optimisation algorithms. Real-time online analytics will be used to quantify each reaction, thus providing robust and standardised datasets for use in predictive machine learning models, enabling their application towards currently underexplored chemistries.Creation of digitally coupled reactors across multiple sites for the exploration of wide process spaces. To achieve this, complementary analytical techniques and different reactor technologies will be leveraged to generate datasets across different scales. Parallelised optimisations will consider the trade-offs between multiple objectives, enabling the sustainability of manufacturing to be considered from the outset of pharmaceutical development.Combination of different types of data across multiple experimental labs to generate hypotheses for new library synthesis and process optimisation campaigns. Next generation machine learning algorithms will be designed to use prior knowledge of contextually similar chemical systems, with the aim of accelerating the transition from discovery to manufacturing.Demonstration of a pilot-scale manufacturing process. Our network of digitally coupled reactors will be used to perform parallelised library synthesis and self-optimisation of a selected process. Scale-up will be evaluated using the facilities available within the iPRD at Leeds.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
水稻边界发育缺陷突变体abnormal boundary development(abd)的基因克隆与功能分析
Development of a Linear Stochastic Model for Wind Field Reconstruction from Limited Measurement Data
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    40万元
  • 批准年份:
    2020
  • 负责人:
    Vikrant Gupta
  • 依托单位: